# Nuclide record zircon (trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/trials/zircon/>
  a schema:MedicalTrial ;
  nuclide:kind "trial" ;
  schema:identifier "zircon", "NCT03849118" ;
  schema:name "ZIRCON"@en ;
  schema:alternateName "89Zr-girentuximab phase 3 trial"@en ;
  schema:description "A single PET scan with a radioactive antibody (89Zr-girentuximab, brand TLX250-CDx) can tell whether an unexplained kidney lump is a clear cell kidney cancer before surgery, so some patients might be spared an unnecessary biopsy or operation."@en ;
  schema:url <https://nuclide.cc/trials/zircon/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/39270701/>, <https://clinicaltrials.gov/study/NCT03849118> ;
  nuclide:status "completed" ;
  nuclide:tag "diagnostic trial", "renal cell carcinoma", "immuno-PET" ;
  nuclide:phase "3" ;
  nuclide:related <https://nuclide.cc/drugs/girentuximab-zr89/>, <https://nuclide.cc/technologies/caix-pet/>, <https://nuclide.cc/indications/rcc/>, <https://nuclide.cc/companies/telix/>, <https://nuclide.cc/isotopes/zr-89/> .